Buying Buzz: Kezar Life Sciences Inc. [KZR] Director BERGER FRANKLIN M acquires 20,000 shares of the company

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kezar Life Sciences Inc. shares valued at $295,400 were purchased by BERGER FRANKLIN M on Mar 21. At $14.77 per share, BERGER FRANKLIN M acquired 20,000 shares. The insider’s holdings grew to 890,691 shares worth approximately $8.91 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, BERGER FRANKLIN M purchased 60,000 shares, netting a total of over 1,004,400 in proceeds. Following the buying of shares at $16.74 each, the insider now holds 870,691 shares.

Before that, Kauffman Michael had sold 5,000 shares from its account. In a trade valued at $82,250, the Director traded Kezar Life Sciences Inc. shares for $16.45 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $0.64 million.

As published in their initiating research note from Wells Fargo on December 08, 2021, Kezar Life Sciences Inc. [KZR] has been an Overweight and the price target has been revised to $19. This represents a 47.37% premium over Thursday’s closing price. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid July. As of July 16, 2018, Wells Fargo has initiated its “an Outperform” rating for KZR. Earlier on July 16, 2018, Jefferies initiated its rating. Their recommendation was “a Buy” for KZR stock.

Analyzing KZR’s Price Performance

On Thursday, Kezar Life Sciences Inc. [NASDAQ: KZR] rose 1.11% to $10.00. The stock’s lowest price that day was $9.81, but it reached a high of $10.41 in the same session. During the last five days, there has been a surge of approximately 1.83%. Over the course of the year, Kezar Life Sciences Inc. shares have dropped approximately -40.19%. Shares of the company reached a 52-week high of $18.55 on 03/18/22 and a 52-week low of $4.30 on 06/13/22. A 50-day SMA is recorded $7.64, while a 200-day SMA reached $11.47. Nevertheless, trading volume fell to 1.31 million shares from 0.46 million shares the previous day.

Support And Resistance Levels for Kezar Life Sciences Inc. (KZR)

According to the 24-hour chart, there is a support level at 9.74, which, if violated, would cause prices to drop to 9.47. In the upper region, resistance lies at 10.34. The next price resistance is at 10.67. RSI (Relative Strength Index) is 60.04 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.03, which suggests the price will decrease in the coming days. Percent R is at 48.92%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Kezar Life Sciences Inc. subject to short interest?

Stocks of Kezar Life Sciences Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.88 million shares to 5.37 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 4.49 million shares. A jump of 16.39% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.11 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.11.

Which companies own the most shares of Kezar Life Sciences Inc. (KZR)?

According to Bellevue Asset Management AG filings, the company currently owns 4,668,148 shares, which is about 7.73% of the total KZR shares outstanding. The investor’s shares have plunged by -250,000 from its previous 13-F filing of 4918148.0 shares. With the completion of the buy transaction, Avidity Partners Management LP’s stake is now worth $29,093,860. Suvretta Capital Management LLC acquire a 122.83% interest valued at $25.98 million while Millennium Management LLC purchased a 2,104,566 stake. A total of 205,548 shares of Kezar Life Sciences Inc. were bought by BlackRock Fund Advisors during the quarter, and 0 were sold by Franklin Advisers, Inc. In its current portfolio, Point72 Asset Management LP holds 2,265,287 shares valued at $18.73 million.

In terms of Kezar Life Sciences Inc. share price expectations, FactSet research, analysts set an average price target of $19.75 in the next 12 months, up nearly 102.22% from the previous closing price of $9.89. Analysts anticipate Kezar Life Sciences Inc. stock to reach $22.00 by 2022, with the lowest price target being $17.00. In spite of this, 6 analysts ranked Kezar Life Sciences Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here